Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089553 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT04089553 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 59 participants.
The verdict
NCT04089553, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred to as modules). Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2: AZD4635 plus oleclumab.
Interventions
- DRUG Durvalumab
- DRUG Oleclumab
- DRUG AZD4635
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2023-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089553
The ClinicalTrials.gov registry entry for NCT04089553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT04089553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04089553 about?
NCT04089553 is a clinical study titled "An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer". This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred to as modules). Combinations to be studied include: 1) Module 1: AZD46...
What is the current status of trial NCT04089553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2019-08-29. Estimated completion is 2023-04-11.
What interventions are being tested in trial NCT04089553?
The interventions under investigation include: Durvalumab (DRUG), Oleclumab (DRUG), AZD4635 (DRUG).
Who is sponsoring clinical trial NCT04089553?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.